George Bakris, MD, Lauds FIDELIO-CKD Findings, Discusses Finerenone

Finerenone, a non-steroidal, selective MRA, has distinct advantages over current treatments for diabetic kidney disease. Dr Bakris details these and the FIDELIO results.

In the phase 3 FIDELIO-DKD trial, finerenone, a non-steroidal, selective mineralocorticoid receptor antagonist (MRA), slowed the progression of diabetic kidney (DKD) disease in patients with type 2 diabetes by 18% over a median of 2.6 years vs the current standard of care. Finerenone also reduced the composite cardiovascular outcome by 14%.

The results were published online October 23, 2020 in the New England Journal of Medicine. 

FIDELIO primary investigator George Bakris, MD, spoke recently with Patient Care about the study and its results in detail. Dr Bakris also describes the properties of finerenone that differentiate the drug from current treatments for DKD and its potential to fill a large unmet clinical need.

Dr Bakris is professor of medicine at the University of Chicago and director of the Comprehensive Hypertension Center at the University of Chicago Medicine. He will present results of an additional FIDELIO analysis at the virtual American Heart Association 2020 Scientific Sessions on Monday, November 16, 2020

Related Videos
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
© 2023 MJH Life Sciences

All rights reserved.